Novartis will pay $125 million up front for rights to a delivery platform designed to get drugs into the brain.
Sironax, a Boston-area biotechnology company, said Tuesday that Novartis has exercised an option to acquire full ownership of that startup’s brain delivery platform. Sironax’s technology is meant to overcome a major challenge in neurological drug development: delivering therapeutics across the “blood-brain barrier.”
Sironax will receive the nine-figure payout following the close of the transaction and will continue to retain rights to develop, manufacture, and commercialize certain assets with the platform. The company currently has three programs in early-stage trials that it plans to move forward using the purchase proceeds.
“This achievement comes at a pivotal time as we advance our clinical-stage pipeline and accelerate the development of promising new therapies,” said Shefali Agarwal, President and CEO of Sironax, in a statement.
Developing medications that can cross the blood-brain barrier has been a critical challenge for both small startups and large pharmaceutical companies. This obstacle acts like a protective filter, shielding the organ from toxic substances as well as beneficial medicines. Several companies have emerged with new technologies to get around this challenge, such as Aerska, Manifold Bio and Korsana Biosciences.
Sironax is among them, too, and gained the attention of Novartis. Through an agreement inked last year, the Swiss pharma secured an “option period” to evaluate Sironax’s platform as well as an exclusive chance to later acquire it. Under that deal, Sironax would be eligible for up to $175 million in upfront and milestone payments.
by Delilah Alvarado
Source: biopharmadive.com
Following the news that longtime helmsman Paul Chaplin would be hanging up his hat at Bavarian Nordic earlier this year, the Danish vaccine maker has found a CEO replacement whose CV spans leadership roles across Sanofi, AstraZeneca and Pfizer.
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a major rebranding as the drugmaker simplifies both its name and image. Novo Nordisk has announced that it will now be known as Novo.
Stefan Doboczky has served as Chairman of the Board of Directors of Hovione since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman upon assuming the role of Chief Executive Officer.
